Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
A diagnosis of multiple myeloma (MM) brings few certainties beyond emotional turmoil on the part of the patient and caregivers. However, a peripheral blood stem cell transplant does have one certainty… well, two actually.
First, it is high-dose chemotherapy and therefore extremely toxic. Secondly, it is not curative. Please don’t take my word for it. Ask your onc if an autologus stem cell transplant will cure your myeloma (remember that conventional oncology considers five years from diagnosis to be a “cure”). Certainly, we all hope for a long remission. But all MMers relapse eventually.
Please take a moment to watch a brief video below about the Multiple Myeloma Coaching Program that I researched and designed based on my 25 plus years living with multiple myeloma:
Autologous stem cell transplant (ASCT) is an established frontline standard of care for the younger, fitter patients with newly diagnosed multiple myeloma (NDMM) who are eligible for the procedure, and has contributed to improved overall survival.
In the current era of novel therapies, the treatment landscape and prognosis have changed. The outstanding efficacy seen with regimens based on novel agents has led to a questioning of the frontline treatment paradigm with respect to ASCT.
A key current question is whether to use transplant early or to collect stem cells early but save ASCT for salvage therapy. In this review, we evaluate the clinical data for each approach as well as the arguments in favor of early or delayed ASCT.
We also consider the clinical/clonal heterogeneity of myeloma and review the evidence regarding which patient subgroups may benefit most from each approach. We summarize current treatment guidelines for transplant-eligible patients with NDMM and review the evolving role of minimal residual disease evaluation and its potential effect on the debate over early vs delayed ASCT. We conclude that frontline ASCT remains a standard of care for a substantial proportion of patients; however, delayed/salvage ASCT is increasingly being used in the context of highly active frontline regimens based on novel agents and the ongoing personalization of myeloma treatment.”